MATRIX PHARMACEUTICAL RECEIVES APPROVALS FOR HUMAN CLINICAL TRIALS IN CANCER
MATRIX PHARMACEUTICAL RECEIVES APPROVALS FOR
HUMAN CLINICAL TRIALS IN CANCER
MENLO PARK, Calif., Nov. 18 /PRNewswire/ -- Matrix Pharmaceutical, Inc. today announced the approval of two Investigational New Drug (IND) applications from the Food and Drug Administration (FDA) to begin Phase I/II clinical trials for the treatment of life-threatening cancers including head and neck cancer and prostate cancer. Nine clinical studies will be conducted at major U.S. cancer treatment centers.
The IND's cover Matrix's anti-cancer drugs, MPI 5011 and MPI 5004, which are site-specific, sustained-release, injectable therapeutics containing proven anti-cancer drugs, protein carriers and vasoconstrictors. In the company's proprietary approach to treatment, compounds are delivered directly to diseased tissues and held in place by protein carriers. This approach concentrates drug activity at the site and reduces side effects that are often associated with systemic administration.
"We are pleased with the IND approvals for our anti-cancer therapeutics and expect that they will further our efforts in the treatment of skin disorders and cancer," said Craig R. McMullen, chief executive officer of Matrix. "In the new trials, we look forward to demonstrating that the treatment of life-threatening cancers is one of many promising applications for our proprietary site-specific products."
The newly approved IND protocols provide for the use of MPI 5011 in the treatment of such cancers as prostate cancer and liver cancer. Indications for MPI 5004 will include head and neck cancer and prostate cancer.
Matrix Pharmaceutical, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of proprietary site-specific therapeutics for cancer and skin diseases. To date, the company has a total of four drugs in human clinical studies. Based in Menlo Park, Calif., Matrix Pharmaceutical was incorporated in 1985 and currently has 35 employees.
/CONTACT: Beverly Holley of Matrix Pharmaceutical, 415-326-6100; or Karen Bergman of Burns McClellan, 212-545-1919, for Matrix Pharmaceutical/ CO: Matrix Pharmaceutical Inc. ST: California IN: MTC SU: FC-SH -- NY012 -- 1237 11/18/91 08:54 EST